4:53 PM
Jan 08, 2010
 |  BC Extra  |  Clinical News

Cyclacel jumps on seliciclib data

Shares of Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) continued to gain on Friday after the company reported preclinical data on Thursday for seliciclib in non-small cell lung cancer (NSCLC)....

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >